Vicore Pharma Holding
Vicore Pharma: Q4 Comment (Redeye)

2021-03-01 07:20
Redeye notes that the Q4 report from Vicore did not include any major surprises. We provide a brief comment on the financials and highlight the most important events during the period. Our Base case remains at SEK 62 per share.

info@redeye.se (Redeye.se)
Redeye AB - Redeye.se

Vicore Pharma Holding - I dag

{point.key}

Marknadsöversikt

Stockholmsbörsen, OMXS30

I dag
-
Senast
-
{point.key}

Världsindex

Index +/- % Senast
DAX - -
Hang Seng - -
Nikkei - -

Valutor

Valuta +/- % Senast
USD/SEK - -
EUR/SEK - -
GBP/SEK - -
EUR/USD - -

Räntor

Ränta +/- % Senast
5-års ränta - -
10-års ränta - -

Råvaror

Råvara +/- % Senast
Guld - -
Silver - -
Koppar - -